TEVATeva Pharmaceutical Industries Limited
Is the price fair?
Priced for +11% a year vs −2% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~11% a year FCF growth. The price already bakes in strong, sustained growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What TEVA's price assumes
Teva Pharmaceutical Industries Limited trades at 68.5× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · 3.48× the median: the market pays up for this one
- Price / sales
- 2.78
Price / sales · as of 2026-Q2
- Free cash flow yield
- 3.4%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; the business has delivered +4.7% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 5.05
- EV / EBITas of 2026-Q2
- 25.0
- EV / salesas of 2026-Q2
- 2.84
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Free cash flow, trailing twelve months
- $1.35B
- Market capitalisation
- $39.1B
- 3-year revenue growth
- −2.1%
- 3-year free cash flow growth
- +4.7%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #14 of 41 by RyuScore